Abstract:e13097 Background: Triple negative breast cancer (TNBC) is an orphan disease that attacks > 46,000 US women every year. TNBC recurs after standard-of-care surgery, chemotherapy and radiation, killing half its victims within 4 years. Poly(ADP-ribose) polymerase (PARP) inhibitors, topoisomerase inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates extend the survival of a fraction of TNBC patients for a few months. Thus, TNBC shows a critical need for molecularly-targeted therapy. Most TNBC cells show high microRNA 21 (miR-21), identical in humans and mice, which decreases tumor suppressor proteins that keep cell growth in check. Hypothesis: Short anti-miR-21 RNA analogs conjugated to a receptor ligand will direct TNBC cell uptake and slow the growth of TNBC orthotopic allografts with immune activation and minimal toxicity. Methods: We designed an anti-miR-21 RNA analog using aminomethyl bridged nucleic acid (BNA), exhibiting low toxicity, and serum stability. We lipofected a concentration ramp of the anti-miR-21 RNA analog into human TNBC cell lines (MDA-MB-231, MDA-MB-157, MDA-MB-436, MDA-MB-468, BT-20, BT-549, HCC1806, HCC1937, HCC1806) representing a spectrum of TNBC subtypes, then measured proliferation and biochemical markers. We also conjugated a peptide analog for endocytosis by the insulin-like growth factor 1 receptor (IGF1R), overexpressed in most TNBC lesions. The peptide ligand for IGF1R provides a unique strategy for delivering the anti-miR-21 RNA analog preferentially into TNBC cells. We administered 5 mg/kg of the anti-miR-21 RNA-peptide analog in sterile saline intraperitoneally twice a week for 14 days into immunocompetent female Balb/c mice bearing syngeneic EMT6 TNBC tumors in their mammary fat pads. Results: The anti-miR-21 RNA analog slowed proliferation, increased apoptosis, elevated tumor suppressor proteins, and suppressed immune checkpoint gene expression in multiple human TNBC lines. IC50 for inhibiting cell proliferation correlated with miR-21 copies/cell in 7 TNBC cell lines, but not in the non-tumorigenic breast epithelial cell line MCF-10A. The anti-miR-21 RNA-peptide analog stopped orthotopic TNBC allograft growth in syngeneic immunocompetent female Balb/c mice during 14 days of therapy, with apparent safety. Conclusions: This strategy optimizes cancer cell-specific delivery to block proliferation and immune checkpoints. The results support further preclinical proof-of-concept studies to enable an eIND submission for the anti-miR-21 RNA-peptide analog.

Bioengineered Mir‐328‐3p Modulates SLC2A1/GLUT1‐mediated Glucose Uptake and Metabolism to Exert Synergistic Antiproliferative Effects with Chemotherapeutics

Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions

The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug

Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia Coli is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy.

Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting Mir-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells

MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)

Mir-3656 Expression Enhances the Chemosensitivity of Pancreatic Cancer to Gemcitabine Through Modulation of the RHOF/EMT Axis.

Up-Regulation Of Mir-221 Mediates The Pioglitazone-Induced Inhibition Of Vascular Endothelial Cell Proliferation

Effect of microRNA-21 blockade in human triple negative breast cancer allografts on progression and immune checkpoint proteins.

In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy

Mir-23B-3p Suppressing PGC1α Promotes Proliferation Through Reprogramming Metabolism in Osteosarcoma

Identification of Novel miRNAs, Targeting Genes, Signaling Pathway, and the Small Molecule for Overcoming Oxaliplatin Resistance of Metastatic Colorectal Cancer

Mir-532–3P Suppresses Proliferation and Invasion of Ovarian Cancer Cells Via GPNMB/HIF-1α/HK2 Axis

Cell membrane camouflaged mesoporous bioactive glass nanoparticles embedding glucose oxidase for enhancing targeted anti-tumor catalytic therapy

Biomimetic Nanomedicine Targeting Orchestrated Metabolism Coupled with Regulatory Factors to Disrupt the Metabolic Plasticity of Breast Cancer.

Decreased Mir-106A Inhibits Glioma Cell Glucose Uptake and Proliferation by Targeting SLC2A3 in GBM

Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy

Role Of Microrna Mir-27a And Mir-451 In The Regulation Of Mdr1/P-Glycoprotein Expression In Human Cancer Cells

Remodeling of Mitochondrial Metabolism by a Mitochondria‐Targeted RNAi Nanoplatform for Effective Cancer Therapy

Polymer‐initiating Caveolae‐mediated Endocytosis and GSH‐responsive MiR‐34a Gene Delivery System for Enhanced Orthotopic Triple Negative Breast Cancer Therapy